3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
19
Lymphoma
19
Lymphoma, Mantle-Cell
17
Leukemia, Lymphocytic, Chronic, B-Cell
15
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, B-Cell, Marginal Zone
10
Lymphoma, B-Cell
10
Lymphoma, Non-Hodgkin
9
Recurrence
6
Hodgkin Disease
6
Waldenstrom Macroglobulinemia
5
Neoplasms
3
Multiple Myeloma
3
Leukemia
3
Burkitt Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphatic Diseases
2
Leukemia, Hairy Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Diseases
2
Sezary Syndrome
1
Proteostasis Deficiencies
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Interventions
pembrolizumab
119
Cisplatin
33
lenvatinib
29
Carboplatin
28
Paclitaxel
27
Docetaxel
14
Pemetrexed
13
Fluorouracil
12
Capecitabine
11
Saline Solution
10
Oxaliplatin
10
Gemcitabine
10
Albumin-Bound Paclitaxel
7
olaparib
6
Leucovorin
6
Bevacizumab
6
epacadostat
5
belzutifan
5
Etoposide
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enzalutamide
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Radiotherapy
3
Levoleucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Bendamustine Hydrochloride
×
1 year
×
Clear all
NCT05508867
2026-01-20
MK-4280A-008
Merck Sharp & Dohme LLC
Phase 2
Completed
203 enrolled